Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

L1295

Sigma-Aldrich

Lamivudine

≥98% (HPLC), powder

Synonym(s):

2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Sign Into View Organizational & Contract Pricing

Select a Size

5 G
¥152.62
100 G
¥211.74
500 G
¥308.48

¥152.62

Available to ship on2025年4月27日Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 G
¥152.62
100 G
¥211.74
500 G
¥308.48

About This Item

Empirical Formula (Hill Notation):
C8H11N3O3S
CAS Number:
134678-17-4
Molecular Weight:
229.26
MDL number:
MFCD00869739
UNSPSC Code:
12352200
PubChem Substance ID:
329817388
NACRES:
NA.77

¥152.62

Available to ship on2025年4月27日Details

Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

water: 10 mg/mL, clear

originator

GlaxoSmithKline

storage temp.

room temp

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
603864106631T36609
p-Toluic acid 98%

T36803

p-Toluic acid

p-Toluic acid-α-13C 99 atom % 13C

603864

p-Toluic acid-α-13C

p-Toluoyl chloride 98%

106631

p-Toluoyl chloride

m-Toluic acid ReagentPlus®, 99%

T36609

m-Toluic acid

assay

98%

assay

-

assay

98%

assay

99%

Quality Level

100

Quality Level

200

Quality Level

200

Quality Level

100

bp

274-275 °C (lit.)

bp

274-275 °C

bp

225-227 °C (lit.), 95-96 °C/10 mmHg (lit.)

bp

263 °C (lit.)

mp

177-180 °C (lit.)

mp

177-180 °C

mp

−4-−2 °C (lit.)

mp

107-113 °C (lit.)

Application

Lamivudine has been used to deplete the Hepatitis B Virus (HBV) covalently closed circular DNA (cccDNA) forms for the preparation of inverse nested PCR.[1]

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    0000328443
    0000328443
    0000227242
    0000227241
    0000227241

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Raph L Hamers et al.
    Journal of acquired immune deficiency syndromes (1999), 64(2), 174-182 (2013-07-31)
    This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes. A multicenter prospective cohort of HIV-infected
    Chia-Yen Dai et al.
    The Journal of antimicrobial chemotherapy, 68(10), 2332-2338 (2013-06-27)
    For hepatitis B e antigen (HBeAg)-positive patients, continuing therapy (consolidation) for 6-12 months before cessation of nucleos(t)ide analogues (NAs) was recommended. This study aimed to investigate whether a longer period of lamivudine consolidation therapy leads to better outcomes and the
    Sharon L Walmsley et al.
    The New England journal of medicine, 369(19), 1807-1818 (2013-11-08)
    Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified
    Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles
    Tu T, et al.
    Journal of virology, JVI-02007 (2018)
    Edward J Gane et al.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(3), 268-274 (2013-03-01)
    Without effective prophylaxis, liver transplantation for hepatitis B virus (HBV)-related liver disease is frequently complicated by severe and rapidly progressive HBV recurrence. Combination prophylaxis with hepatitis B immune globulin (HBIG) and lamivudine (LAM) reduces long-term recurrence rates below 10%; however
    View All Related Papers

    Articles

    Bioactive Molecules for Immunology Research

    Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

    Discover Bioactive Small Molecules for ADME/Tox

    Discover Bioactive Small Molecules for ADME/Tox

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service